Compare AAOI & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAOI | APLS |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2013 | 2015 |
| Metric | AAOI | APLS |
|---|---|---|
| Price | $106.28 | $18.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 20 |
| Target Price | ★ $66.80 | $31.89 |
| AVG Volume (30 Days) | ★ 7.4M | 1.7M |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 85.78 | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $120.31 | N/A |
| Revenue Next Year | $126.89 | $17.97 |
| P/E Ratio | ★ N/A | $96.85 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $9.72 | $16.10 |
| 52 Week High | $128.96 | $30.48 |
| Indicator | AAOI | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 65.22 | 26.61 |
| Support Level | $24.13 | $16.89 |
| Resistance Level | N/A | $20.42 |
| Average True Range (ATR) | 10.17 | 0.93 |
| MACD | 3.86 | -0.21 |
| Stochastic Oscillator | 71.73 | 0.46 |
Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.